FIELD: medicine; pharmaceutics.
SUBSTANCE: first object represents a pharmaceutical composition containing an anti-CD20 antibody representing divosilimab, acetate buffer, sorbitol, methionine and water for injections. Second object is the use of the pharmaceutical composition for treating a CD20-mediated disease or disorder in a subject in need thereof. Third object is a method of treating a CD20-mediated disease or disorder involving administering a pharmaceutical composition to a subject in need thereof in a therapeutically effective amount.
EFFECT: storage stability of pharmaceutical compositions of anti-CD20 antibodies of divosilimab, which can be used as a drug for treating diseases or disorders mediated by CD20.
53 cl, 7 dwg, 13 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION OF ANTI-TRBV9 ANTIBODY AND USE THEREOF | 2022 |
|
RU2826886C1 |
RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-IL17A ANTIBODY AND ITS APPLICATION | 2019 |
|
RU2754760C2 |
ANTIBODY PREPARATION | 2008 |
|
RU2476238C2 |
PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND USE THEREOF | 2021 |
|
RU2791857C2 |
APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TO CD20 | 2018 |
|
RU2724469C2 |
Authors
Dates
2024-08-12—Published
2022-10-26—Filed